HDAC6 and peripheral neuropathy: Peripheral neuropathy was minimised in preclinical models with the coadministration of a histone deacetylase 6 inhibitor, suggesting that combination approaches may help mitigate the neurotoxic effects associated with OXPHOS inhibitors50,51.